How Ph.D. was paid
$7.7M in total for fiscal 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Options | Incentive | Other | Total |
|---|---|---|---|---|---|
| Clay Siegall, Ph.D.President, Chief Executive Officer and Chairman of the Board | $735,000 | $6,272,810 | $661,500 | $13,291 | $7,682,601 |
| Max RosettChief Financial Officer | $472,500 | $1,623,090 | $278,800 | $411,167 | $2,785,557 |
| Robert Lechleider, M.D.Chief Medical Officer | $530,300 | $1,897,525 | $307,600 | $12,193 | $2,747,618 |
What changed and why
- $7.7MClay Siegall received total compensation of $7,682,601 in fiscal 2025, representing a decrease from the prior year.
- 5%Base salary for the CEO increased 5% from 2024 to 2025 to reach $735,000.
- 150%The CEO earned an annual performance bonus of $661,500, reflecting achievement at 150% of target.
- $6.3MLong-term incentives were delivered through stock option grants, with the CEO receiving option awards valued at $6,272,810.
- 60%Development and CMC performance goals carried a 60% weighting and were exceeded during the fiscal year.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.